Search clinical trials for: AMN107- NILOTINIB

Total 3020 results

Novartis Pharmaceuticals

Completed

Tasigna in Glivec-resistant or Intolerant Patients in CML

CML | Nilotinib | Imatinib Resistant | Imatinib Intolerant

Korea, Republic of
Novartis Pharmaceuticals

Approved for marketing

Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Mexico
Georgetown University

Unknown

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
University Hospital, Bordeaux

Completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Seoul National University Hospital

Completed

Effect of Nilotinib in Cerebellar Ataxia Patients

Ataxia, Cerebellar | Ataxia, Progressive

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway
Asan Medical Center

Completed

Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK

Gastrointestinal Stromal Tumors

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib (MACS1532)

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Russian Federation
Novartis Pharmaceuticals

Completed

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor

Turkey
Novartis Pharmaceuticals

Completed

Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (MACS0439)

Chronic Myeloid Leukemia

Brazil
Samsung Medical Center

Unknown

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Leukemia, Chronic Myeloid
Northwestern University
University of Iowa; University of Rochester; Michael J. Fox Foundation for Parkinson...

Completed

Nilotinib in Parkinson's Disease (NILO-PD)

Parkinson Disease

United States
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Aurigene Discovery Technologies Limited

Recruiting

A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

Relapsed Malignant Solid Neoplasm

India
Georgetown University
National Institutes of Health (NIH)

Recruiting

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States
Institut Bergonié
Novartis Pharmaceuticals

Withdrawn

Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer (ZAK-0)

Colon Cancer

France
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
Fox Chase Cancer Center

Terminated

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) (07060)

Gastrointestinal Stromal Tumors

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Germany, Australia, Italy, Hong Kong, India, Singapore, Canada, Korea, Republic of, United Kingdom, New Zealand, Ireland, France, Poland, Japan, Switzerland, Croatia, Belgium, Malaysia and more
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Chronic Phase Chronic Myeloid Leukemia

United States
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Cervical Cancer
Institute of Hematology and Blood Transfusion,...
CZECRIN - Czech Clinical Research Infrastructure Network

Completed

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) (Blina-CELL)

Newly Diagnosed | Lymphoblastic Leukemia, Acute, Adult | Ph Negative ALL

Czechia
Li Peng
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (Icotinib)

Neurofibromatosis Type 2 | Vestibular Schwannoma

China
University of Michigan Rogel Cancer Center

Withdrawn

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Leukemia, Chronic Myeloid

United States
Novartis Pharmaceuticals

Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Germany, Canada, France, Spain, Italy
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)

Chronic Myeloid Leukemia

Germany
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Anhui Medical University

Unknown

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

NSCLC

China
AstraZeneca
Amgen

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma (HORIZON)

Asthma

United States, Poland, Korea, Republic of, Spain, France, China, United Kingdom, Canada, Netherlands, Argentina, Mexico, Brazil, Hungary, Japan, Philippines, South Africa, Colombia
Galapagos NV
Gilead Sciences

Active, not recruiting

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (FINCH 4)

Rheumatoid Arthritis

Spain, United States, Japan, Korea, Republic of, Taiwan, Belgium, India, Malaysia, Argentina, Australia, Poland, Czechia, Serbia, Germany, New Zealand, Bulgaria, Canada, Chile, France, Hong Kong, Hungary, Ireland, Israel, Italy, Mexico, R... and more
Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
Fox Chase Cancer Center
Novartis

Terminated

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Metastatic Disease | GIST

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

NSCLC

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Event-free Lifetime

China
Zhejiang Cancer Hospital

Recruiting

Anlotinib to Malignant Brainstem Glioma

Glioma | Malignant Brain Stem Tumor

China
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Feng Wang

Completed

Anlotinib Retrospective Study for Esophageal Cancer

Esophageal Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Unknown

Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC (CSOAIMTOAN)

Nonsmall Cell Lung Cancer

China

Search clinical trials for: AMN107- NILOTINIB

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations